Seeking Alpha
View as an RSS Feed

BioCourse AP  

View BioCourse AP's Articles BY TICKER:
  • The Stage Is Set For Investors To Realize Huge Gains With Ocera Therapeutics
    Tue, Jan. 6 OCRX 29 Comments


    • Per the company's recent December presentation, 3 Phase 2 studies will present data this year.
    • Preliminary data from the 2 sponsored studies demonstrated efficacy and safety with OCR-002. The data helps to de-risk the investment.
    • According to, as of 9/30/14, there were 7,030,784 shares held by 31 institutions. This represents a 59.92% increase from the previous reporting period of 6/30/14.
  • Ocera Therapeutics Finally Ready To Reward Investors
    Oct. 1, 2014 OCRX 10 Comments


    • Ocera's stock price has fallen dramatically in 2014, however the contributing events have now created an incredible buying opportunity.
    • OCR-002 has received orphan drug and fast track status. There are three Phase 2 trials ongoing of which two presented preliminary data demonstrating all 24 patients have fully recovered.
    • The company will be presenting at the Bio Investor Forum on October 7th and should be providing a more precise timeline for top line data.
    • Ocera is grossly undervalued with a market cap of $94 million and a product with peak sales potential of $1.5 billion.
    • With cash on hand through 2016, a lead product expected to be the new standard of care, and imminent data results, Ocera is a compelling low risk high reward investment.
  • Ocera Therapeutics: Setting Up To Breakout
       • Feb. 27, 2014 OCRX 14 Comments